Uveitis associated with concurrent administration of rifabutin and lopinavir/ritonavir (Kaletra)

Lin, H-C; Lu, P-L; Chang, C-H

doi:10.1038/sj.eye.6703016

Correspondence
Published: 26 October 2007

Uveitis associated with concurrent administration of rifabutin and lopinavir/ritonavir (Kaletra)

H-C Lin^1,2,
P-L Lu³ &
C-H Chang^1,4

Eye volume 21, pages 1540–1541 (2007)Cite this article

1660 Accesses
11 Citations
9 Altmetric
Metrics details

A 41-year-old HIV-infected man received lamivudine/zidovudine and nevirapine therapy. He also took isoniazid/rifampicin/pyrazinamide and ethambutol for pulmonary tuberculosis. Because skin rash appeared, nevirapine was replaced by lopinavir/ritonavir 400/100 mg twice daily. The antituberculosis regimens were replaced by rifabutin 300 mg/day and methaniazide 600 mg/day because of known interactions between lopinavir/ritonavir and rifampicin.¹

Conditions associated with uveitis in HIV-positive patients include opportunistic infection, neoplasms, inflammation due to HIV infection itself, and drug toxicities.² The patient was negative for HLA-B27 and syphilis. Uveitis did not recur after discontinuing rifabutin for one year. Refabutin was suspected as the cause of uveitis by evidences of timing condition, lack of other causes, and resolution after stopping the implicated drug.

References

Oldfield V, Plosker GL . Lopinavir/ritonavir: a review of its use in the management of HIV infection. Drugs 2006; 66: 1275–1299.
Article CAS Google Scholar
Cunningham Jr ET . Uveitis in HIV positive patients. Br J Ophthalmol 2000; 84: 233–235.
Article Google Scholar
Saran BR, Maquire AM, Nichols C, Frank I, Hertle RW, Brucker AJ et al. Hypopyon uveitis in patients with acquired immunodeficiency syndrome treated for systemic Mycobacterium avium complex infection with rifabutin. Arch Ophthalmol 1994; 112: 1159–1165.
Article CAS Google Scholar
Skinner MH, Blaschke TF . Clinical pharmacokinetics of rifabutin. Clin Pharmacokinet 1995; 28: 115–125.
Article CAS Google Scholar
Kuper JI, D'Aprile M . Drug–drug interactions of clinical significance in the treatment of patients with Mycobacterium avium complex disease. Clin Pharmacokinet 2000; 39: 203–214.
Article CAS Google Scholar
Cato III A, Cavanaugh J, Shi H, Hsu A, Leonard J, Granneman R . The effect of multiple doses of ritonavir on the pharmacokinetics of rifabutin. Clin Pharmacol Ther 1998; 63: 414–421.
Article CAS Google Scholar
Sun E, Heath-Chiozzi M, Cameron DW, Hsu A, Granneman RG, Maurath CJ . Concurrent ritonavir and rifabutin increases risk of rifabutin-associated adverse events. In Volume 1 of Program and abstracts of the 11th International Conference on AIDS, Vancouver, B.C., 7–12 July, 1996: 18 (abstract).
Cvetkovic RS, Goa KL . Lopinavir/ritonavir: a review of its use in the management of HIV infection. Drugs 2003; 63: 769–802.
Article CAS Google Scholar
Corbett AH, Lim ML, Kashuba AD . Kaletra (lopinavir/ritonavir). Ann Pharmacother 2002; 36: 1193–1203.
Article CAS Google Scholar

Download references

Author information

Authors and Affiliations

Department of Ophthalmology, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan
H-C Lin & C-H Chang
Department of Ophthalmology, Yuan's General Hospital, Kaohsiung, Taiwan
H-C Lin
Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan
P-L Lu
Department of Ophthalmology, Kaohsiung Municipal Hsiao-Kang Hospital, Kaohsiung, Taiwan
C-H Chang

Authors

H-C Lin
View author publications
Search author on:PubMed Google Scholar
P-L Lu
View author publications
Search author on:PubMed Google Scholar
C-H Chang
View author publications
Search author on:PubMed Google Scholar

Corresponding author

Correspondence to C-H Chang.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lin, HC., Lu, PL. & Chang, CH. Uveitis associated with concurrent administration of rifabutin and lopinavir/ritonavir (Kaletra). Eye 21, 1540–1541 (2007). https://doi.org/10.1038/sj.eye.6703016

Download citation

Published: 26 October 2007
Issue date: 01 December 2007
DOI: https://doi.org/10.1038/sj.eye.6703016

This article is cited by

Pharmacokinetic study of two different rifabutin doses co-administered with lopinavir/ritonavir in African HIV and tuberculosis co-infected adult patients
- Seni Kouanda
- Henri Gautier Ouedraogo
- Alberto Matteelli
BMC Infectious Diseases (2020)
Pharmacokinetics of plasma lopinavir and ritonavir in tuberculosis–HIV co-infected African adult patients also receiving rifabutin 150 or 300 mg three times per week
- Henri Gautier Ouedraogo
- Alberto Matteelli
- Seni Kouanda
Annals of Clinical Microbiology and Antimicrobials (2020)

Uveitis associated with concurrent administration of rifabutin and lopinavir/ritonavir (Kaletra)

Log in or create a free account to read this content

References

Author information

Authors and Affiliations

Corresponding author

Rights and permissions

About this article

Cite this article

This article is cited by

Pharmacokinetic study of two different rifabutin doses co-administered with lopinavir/ritonavir in African HIV and tuberculosis co-infected adult patients

Pharmacokinetics of plasma lopinavir and ritonavir in tuberculosis–HIV co-infected African adult patients also receiving rifabutin 150 or 300 mg three times per week

Search

Quick links

Log in or create a free account to read this content

References

Author information

Authors and Affiliations

Corresponding author

Rights and permissions

About this article

Cite this article

Share this article

This article is cited by

Pharmacokinetic study of two different rifabutin doses co-administered with lopinavir/ritonavir in African HIV and tuberculosis co-infected adult patients

Pharmacokinetics of plasma lopinavir and ritonavir in tuberculosis–HIV co-infected African adult patients also receiving rifabutin 150 or 300 mg three times per week

Search

Quick links